144 related articles for article (PubMed ID: 18570578)
1. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
2. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
Ozyilkan O; Yalçintaş U; Başkan S
Korean J Intern Med; 1999 Jul; 14(2):15-9. PubMed ID: 10461420
[TBL] [Abstract][Full Text] [Related]
3. A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam).
Coccolini F; Catena F; Ansaloni L; Ercolani G; Di Saverio S; Gazzotti F; Lazzareschi D; Pinna AD
BMC Gastroenterol; 2011 Apr; 11():42. PubMed ID: 21501482
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis.
Wu R; Wang X; Cui P; Chen W; Yang W; Lai Y
J Chemother; 2024 Apr; ():1-11. PubMed ID: 38644652
[TBL] [Abstract][Full Text] [Related]
5. A case of
Wu L; Ye T; Pan X; Hong L; Shi Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 53(1):126-130. PubMed ID: 38105675
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
7. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity vasculitis induced by cefoperazone/sulbactam.
Islek I; Baris S; Katranci AO; Ariturk E; Gurses N
Ann Clin Microbiol Antimicrob; 2003 Jan; 2():1. PubMed ID: 12556245
[TBL] [Abstract][Full Text] [Related]
9. [Metronidazole - spectrum of activity, use and side effects].
Wallner J; Rieder M; Schwaiger M; Pau M; Zrnc T; Zemann W; Metzler P
Swiss Dent J; 2022 Jun; 132(6):433-435. PubMed ID: 35679094
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Frontiers Production Office
Front Pharmacol; 2024; 15():1365927. PubMed ID: 38288439
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
[TBL] [Abstract][Full Text] [Related]
12. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.
Xin X; Jian L; Xia X; Jia B; Huang W; Li C; Wang C; Zhou L; Sun X; Tang X; Huang Y; Zhu Y; Zhang W
Ann Clin Microbiol Antimicrob; 2013 Dec; 12():38. PubMed ID: 24321187
[TBL] [Abstract][Full Text] [Related]
13. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
Jones RN; Barry AL; Thornsberry C; Wilson HW
Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
15. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
[TBL] [Abstract][Full Text] [Related]
17. Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.
Jones RN; Barry AL
Rev Infect Dis; 1983; 5 Suppl 1():S108-26. PubMed ID: 6221381
[TBL] [Abstract][Full Text] [Related]
18. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections.
Jauregui LE; Appelbaum PC; Fabian TC; Hageage G; Strausbaugh L; Martin LF
J Antimicrob Chemother; 1990 Mar; 25(3):423-33. PubMed ID: 2187014
[TBL] [Abstract][Full Text] [Related]
19. [Cefoperazone/sulbactam in continuous infusion].
Woźnica R; Ferenc K; Kurec D
Anestezjol Intens Ter; 2010; 42(2):80-4. PubMed ID: 21413432
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections].
Shinagawa N; Takeda S; Oohira S; Yasuda Y; Fujisaki M; Saito H; Ueda M; Mitamura K; Nishio T; Itakura M; Koyama M; Hirano M; Ohyama R; Kako M; Amako Y; Okuda K; Iwasa T; Sugiyama A; Hirano M; Takashima S; Ohswawa N; Nakaya S; Yamada M; Zeze F; Ishii J
Jpn J Antibiot; 1997 Nov; 50(11):862-70. PubMed ID: 9651604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
